Table 2 Clinical features and laboratory findings differences between severe and non-severe patients

Age

66.0 (24.0–90.0)

65.0 (43.0–90.0)

70.0 (24.0–87.0)

Gender

 Female

47 (45.6%)

35 (52.2%)

12 (33.3%)

 Male

56 (54.4%)

32 (47.8%)

24 (66.7%)

Smoking

20 (19.4%)

8 (11.9%)

12 (33.3%)

Comorbidities

 Diabetes

14 (13.6%)

5 (7.5%)

9 (25%)

 Hypertension

37 (35.9%)

22 (32.8%)

15 (41.7%)

 Heart disease

11 (10.7%)

4 (6.0%)

7 (19.4%)

Symptoms

 Fever

73 (70.9%)

45 (67.2%)

28 (77.8%)

 Cough

70 (68.0%)

49 (73.1%)

21 (58.3%)

 Dyspnea

24 (23.3%)

9 (13.4%)

15 (41.7%)

 Vomiting

5 (4.9%)

2 (3.0%)

3 (8.3%)

 Diarrhea

7 (6.8%)

3 (4.5%)

4 (11.1%)

Laboratory findings

 WBC (× 10⁹/L)

5.29 (1.90–25.10); n = 100

4.77 (1.90–25.10); n = 65

7.16 (2.00–18.80); n = 35

 Neutrophil (× 10⁹/L)

3.49 (0.67–22.40); n = 100

3.00 (0.67–22.40); n = 65

5.27 (1.03–17.36); n = 35

 Lymphocyte (× 10⁹/L)

1.06 (0.22–2.89); n = 100

1.23 (0.33–2.62); n = 65

0.80 (0.22–2.89); n = 35

 NLR

2.93 (0.64–32.23); n = 100

2.29 (0.64–18.39); n = 65

6.93 (1.20–32.23); n = 35

 Monocytes (× 10⁹/L)

0.43 (0.11–9.90); n = 72

0.41 (0.11–9.90); n = 52

0.50 (0.14–1.04); n = 20

 Eosnophils (× 10⁹/L)

0.07 (0.00–0.90); n = 72

0.08 (0.00–0.51); n = 52

0.03 (0.00–0.90); n = 20

 Basophils (× 10⁹/L)

0.02 (0.00–0.11); n = 72

0.02 (0.00–0.11); n = 52

0.02 (0.00–0.05); n = 20

 RBC (× 10¹²/L)

3.95 (2.03–5.77); n = 73

4.01 (2.03–5.14); n = 52

3.53 (2.63–5.77); n = 21

 HB (g/L)

116.00 (68.00–154.00); n = 73

119.00 (68.00–154.00); n = 52

102.00 (79.00–154.00); n = 21

 PLT (× 10⁹/L)

203.00 (53.00–431.00); n = 72

205.00 (67.00–431.00); n = 52

190.00 (53.00–312.00); n = 20

 CRP (mg/L)

2.52 (0.14–280.32); n = 90

1.39 (0.14–137.52); n = 58

42.59 (0.05–280.32); n = 32

 ALT (U/L)

19.17 (4.50–131.20); n = 97

19.05 (4.50–131.20); n = 64

20.70 (6.00–100.30); n = 33

 AST (U/L)

21.70 (10.00–147.20); n = 84

20.45 (10.00–147.20); n = 52

26.70 (12.00–92.60); n = 32

 Total protein (g/L)

64.99 (53.70–87.58); n = 71

65.50 (55.45–87.58); n = 51

60.89 (53.70–78.97); n = 20

 Albumin (g/L)

37.29 (23.60–48.00); n = 71

38.14 (23.60–48.00); n = 51

32.61 (25.30–43.50); n = 20

 Globulin (g/L)

28.00 (17.31–46.24); n = 71

27.30 (17.31–40.49); n = 51

28.20 (24.00–46.24); n = 20

 A/G

1.30 (0.39–2.20); n = 71

1.35 (0.39–2.20); n = 51

1.22 (0.71–1.46); n = 20

 Total bilirubin (umol/L)

10.32 (4.20–44.58); n = 70

10.23 (4.20–33.46); n = 51

11.70 (6.00–44.58); n = 19

 Direct Bilirubin (umol/L)

2.71 (0.00–23.90); n = 70

2.50 (0.00–14.20); n = 51

3.86 (0.00–23.90); n = 19

 Indirect bilirubin (umol/L)

7.39 (2.99–26.42); n = 70

7.32 (3.00–26.42); n = 51

7.90 (2.99–22.68); n = 19

 BUN (umol/L)

4.67 (2.68–29.61); n = 68

4.62 (2.68–29.61); n = 49

5.47 (2.93–18.77); n = 19

 Creatinine (umol/L)

57.72 (13.25–345.35); n = 70

58.17 (31.60–345.35); n = 50

55.15 (13.25–145.39); n = 20

 Uric acid (umol/L)

268.01 (100.00–275.95)); n = 69

304.73 (151.56–575.95); n = 50

163.00 (100.00–547.00); n = 19

 ALP (U/L)

71.10 (42.59–493.30); n = 70

67.80 (42.59–493.30); n = 51

74.60 (55.16–238.00); n = 19

 γ-GT (U/L)

26.47 (8.15–263.60); n = 70

26.30 (8.15–263.60); n = 51

33.62 (11.02–239.60); n = 19

 CK (U/L)

48.40 (10.90–195.90); n = 55

52.67 (16.89–116.73); n = 37

43.14 (10.90–195.90); n = 18

 CKMB (U/L)

7.80 (0.01–54.60); n = 68

7.61 (0.01–54.60); n = 50

7.85 (2.28–49.70); n = 18

 LDH (U/L)

179.90 (2.17–761.70); n = 69

169.13 (2.17–761.70); n = 50

209.66 (116.20–702.30); n = 19

 ɑ-HBDH (U/L)

133.59 (87.75–701.40); n = 66

126.96 (87.75–701.40); n = 48

169.50 (99.79–604.40); n = 18

 D-dimer (mg/L)

0.43 (0.02–27.94); n = 45

0.37 (0.07–4.97); n = 30

1.14 (0.02–27.94); n = 15

 NT-proBNP (U/L)

30.77 (0.01–515.18); n = 22

11.33 (0.01–112.76); n = 11

60.90 (23.94–515.81); n = 11

 Procalcitonin (ng/ml)

0.05 (0.02–0.90); n = 56

0.04 (0.02–0.45); n = 36

0.18 (0.02–0.90); n = 20

 IL-6 (pg/ml)

3.64 (1.50–3392.00); n = 50

2.84 (1.50–268.30); n = 33

29.99 (1.50–3392.00); n = 17